denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.
Program: Education Program
Session: Optimizing Non-Curative Therapies for Sickle Cell Disease
Hematology Disease Topics & Pathways:
Sickle Cell Disease, Combination therapy, Artificial intelligence (AI), Adult, Clinical Practice (Health Services and Quality), Diversity, Equity, and Inclusion (DEI), Education, Hemoglobinopathies, Pediatric, Diseases, Treatment Considerations, Young adult , Technology and Procedures, Study Population, Human, Machine learning
Session: Optimizing Non-Curative Therapies for Sickle Cell Disease
Hematology Disease Topics & Pathways:
Sickle Cell Disease, Combination therapy, Artificial intelligence (AI), Adult, Clinical Practice (Health Services and Quality), Diversity, Equity, and Inclusion (DEI), Education, Hemoglobinopathies, Pediatric, Diseases, Treatment Considerations, Young adult , Technology and Procedures, Study Population, Human, Machine learning
Saturday, December 7, 2024, 9:30 AM-10:45 AM
Disclosures: Bartolucci: Novartis: Consultancy, Other: member advisory board and member steering commitee; Pfizer: Consultancy; Innovhem: Other: Founder; Addmedica: Consultancy, Other: member advisory board; Emmaus: Consultancy; JazzPharma: Consultancy; Bluebird: Consultancy; Roche: Consultancy.
See more of: Optimizing Non-Curative Therapies for Sickle Cell Disease
See more of: Education Program
See more of: Education Program
<< Previous Presentation
|
Next Presentation